SCHEMBL3586690

SCHEMBL3586690

CCOC(=O)Cc1c(Cl)ccc2cc(O)ccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.42
ALDH1A1 P00352 4/20 0.42
CASP1 P29466 3/20 0.42
CASP7 P55210 3/20 0.42
HSD17B10 Q99714 3/20 0.42
GAA P10253 2/20 0.42
HPGD P15428 2/20 0.42
GLA P06280 2/20 0.42
LMNA P02545 5/20 0.41
EGFR P00533 2/20 0.41
MAPT P10636 2/20 0.40
MIF P14174 2/20 0.40
MEN1 O00255 1/20 0.40
AHR P35869 1/20 0.40
KMT2A Q03164 1/20 0.40
ALOX5 P09917 1/20 0.40
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA7 P43166 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL991440 0.90 KDM4E (0.43) KDM4EALDH1A1CASP1CASP7HSD17B10
SCHEMBL3591481 0.84 KDM4E (0.40) KDM4EALDH1A1CASP1CASP7HSD17B10
SCHEMBL3591326 0.84 PTGS2 (0.50) KDM4EALDH1A1HSD17B10GAAHPGD
SCHEMBL3588920 0.82 NCEH1 (0.46) KDM4EALDH1A1CASP1CASP7HSD17B10
SCHEMBL3588780 0.81 CYP4F2 (0.40) KDM4EALDH1A1CASP1CASP7HSD17B10
SCHEMBL3588873 0.78 HSD11B1 (0.39) KDM4EALDH1A1CASP1CASP7HSD17B10
SCHEMBL989998 0.77 KDM4E (0.41) KDM4EALDH1A1HSD17B10HPGDLMNA
SCHEMBL991313 0.77 PTGS2 (0.54) KDM4EALDH1A1HSD17B10GAAHPGD
SCHEMBL136459 0.77 EGFR (0.56) KDM4EALDH1A1GAALMNAEGFR
SCHEMBL27684522 0.76 RAD52 (0.39) ALDH1A1MIFMEN1KMT2AALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691861-B2 Indolymaleimide derivatives NOVARTIS AG (CH) 2010-04-06 US disclosed
US-20080234494-A1 Indolylmaleimide Derivatives NOVARTIS AG (CH) 2008-09-25 US disclosed
EP-1709030-B1 INDOLYLMALEIMIDE DERIVATIVES NOVARTIS AG (CH) 2008-04-02 EP disclosed
EP-1709030-A1 INDOLYLMALEIMIDE DERIVATIVES Novartis AG (CH) 2006-10-11 EP disclosed
WO-2005068454-A1 INDOLYLMALEIMIDE DERIVATIVES NOVARTIS AG (CH) 2005-07-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234494-A1 Indolylmaleimide Derivatives IDH3A, INMT, IDH2 KDM4E 167/4885ALDH1A1 46/4885CASP1 3337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.